Image 1
Chemical structure of finasteride showing its steroidal framework with functional groups including a ketone, amide, and methyl substitutions.*
Finasteride
Product Images NDC 0093-7355
6 FDA label images from Teva Pharmaceuticals Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 0093-7355). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image 2
A line graph comparing the mean change from baseline in a measured variable over four years for Finasteride and placebo groups. The x-axis shows time from baseline to Year 4, and the y-axis shows mean change with standard error. Data points for each year include sample sizes, illustrating a greater decrease in the measured variable for Finasteride compared to placebo over time.*
Image 3
A line chart comparing the cumulative percentage of patients experiencing events over 48 months between Finasteride and Placebo groups. The x-axis represents observation time in months, and the y-axis shows percent of patients. Below the graph, cumulative event counts and number at risk per year are tabulated for both groups.*
Image 4
A line graph comparing mean percent change from baseline over four years for placebo and Finasteride groups. The vertical axis shows mean percent change and the horizontal axis marks baseline through year 4. Placebo data points increase above baseline, while Finasteride data points decline below baseline, showing divergent trends between groups over time.*
Image 5
A line graph titled 'Cumulative Incidence of a 4 Point Rise in AUA Symptom Score by Treatment Group,' showing percent with event over 5.5 years from randomization. Four treatment groups are plotted: Placebo (highest incidence), Finasteride, Doxazosin, and Combination (lowest incidence).*
Image 6
Finasteride Tablets USP 5 mg label by Teva Pharmaceuticals USA, Inc. The label includes the NDC 0093-7355-05 and states the product contains 500 tablets. It features storage and usage instructions, warnings regarding use by women and children, and prescription-only labeling. The design uses red and beige colors with barcode and manufacturer information.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
